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Abstract A human placenta cDNA expression library was
screened for genes inducing flat reversion when transfected into a
v-K-ras-transformed NIH3T3 cell line, DT. One such gene was
found to encode a Kunitz-type serine protease inhibitor, tissue
factor pathway inhibitor-2 (TFPI-2). While the TFPI-2 mRNA
can be detected in normal human fibroblasts (MRC-5), it is
down-regulated in MRC-5 cells expressing an activated H-ras
oncogene and in the human fibrosarcoma cell line, HT1080.
Restored expression of the TFPI-2 gene in HT1080 cells resulted
in the suppression of matrix invasion activity in vitro with
concomitant decrease in the relative amount of active matrix
metalloproteinase-2 secreted from the cells. When DT cells were
cultured in the presence of conditioned medium and extracellular
matrix prepared from TFPI-2-transfected HT1080 cells, in-
creased attachment and flat reversion were observed. These
results suggest that TFPI-2 may be required for the maintenance
of the integrity of extracellular matrix in normal tissues and its
down-regulation as a result of oncogene activation may
contribute to the malignant phenotypes of tumor cells. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
Key words: ras oncogene; Transformation suppressor gene;
Tissue factor pathway inhibitor-2;
Matrix metalloproteinase-2; Tumor invasion
1. Introduction
Mutations of ras proto-oncogenes are found in a large va-
riety of human tumors [1]. Ras proteins are essential compo-
nents in various intracellular signaling pathways involved in
regulating gene expression and several other aspects of cellular
behavior [2^5]. Therefore, it is now important to ¢nd targets
for these signals relevant to the expression of the malignant
phenotype in order to understand the mechanism of cell trans-
formation and to help developing novel strategies for cancer
intervention.
To this end, we have been isolating and characterizing genes
which induce £at, normal ¢broblast-like morphology (or ‘£at
reversion’) when expressed in a v-K-ras-transformed NIH3T3
cell line, DT [6]. Products of such reversion-inducing genes we
characterized so far include a Ras-related small G-protein
(Krev-1/Rap1A) [7,8], a truncated form of the MSX-2 homeo-
box protein [9], and a novel membrane-anchored glycoprotein
(RECK) containing multiple Kazal-type serine protease inhib-
itor-like domains [10]. Interestingly, the expression of the
RECK gene is strongly suppressed in many cell lines derived
from tumors or transformed by various oncogenes [10,11].
Moreover, when the RECK gene was arti¢cially expressed in
¢brosarcoma cells, secretion of matrix proteinase-9 was found
to be reduced and the invasive and metastatic activities of the
cells signi¢cantly suppressed [10].
Here we report on the characterization of another rever-
sion-inducing cDNA encoding a Kunitz-type serine protease
inhibitor, previously termed tissue factor pathway inhibitor-2
(TFPI-2) [12,13] and placental protein 5 (PP5) [14]. TFPI-2 is
an extracellular glycoprotein of about 32 kDa (213 amino acid
residues) and is structurally related to TFPI [12,13]. TFPI is a
plasma protein which inhibits the initial steps of the extrinsic
coagulation pathway and regulates the hemostasis [15,16]. It
also inhibits the proliferation of vascular smooth muscle cells
in culture [17]. In the enzyme assay system in vitro, TFPI-2
was reported to be a strong inhibitor for trypsin, plasmin,
plasma kallikrein and factor XIa amidolytic activity [13]. Lit-
tle is known, however, about the physiological functions of
TFPI-2, except for the ¢nding by Shinoda et al. that it stim-
ulates the proliferation of smooth muscle cells in culture [18].
Our observations reported here indicate that the expression of
TFPI-2 gene is low in cells expressing activated ras oncogenes
and that this may contribute to the morphological changes
associated with cell transformation and the invasive/metastatic
behavior of cancer cells.
2. Materials and methods
2.1. Cell culture
DT cells [6] were cultured in Dulbecco’s modi¢ed Eagle medium
(DME; Gibco) supplemented with 10% fetal calf serum (FCS; JRH
Bioscience), 4 mM L-glutamine, 100 U/ml penicillin G and 100 Wg/ml
streptomycin sulfate. Other cell lines were obtained from ATCC and
maintained according to the supplier’s instruction. MRC-5/H-ras12V
was generated by infecting the MRC-5 normal human ¢broblast
strain [19] with a helper-free stock of LXSN retroviral vector [20]
carrying the activated human H-ras oncogene (H-ras12V) prepared
using the amphotropic packaging host GP+envAm12 [21]. Transfec-
tion with cloned plasmids was carried out using the mammalian trans-
fection kit (Stratagene). For soft agar assay, cells (3U103) were plated
in suspension in minimal essential medium containing 0.33% Bacto-
Agar (Difco), L-glutamine, antibiotics and 10% ¢ltered FCS, and the
colonies were counted under a microscope after 3 weeks incubation.
2.2. Expression cloning of reversion-inducing cDNAs
A cDNA library consisting of 2U106 independent clones was gen-
erated using human placental mRNAs (Clontech) and a newly devel-
oped phagemid-type expression vector carrying blasticidin-S (Bla-S)
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resistance marker BSD (N. Akiyama et al., in preparation). The total
of 200 Wg puri¢ed phage DNA was transfected into 6U106 DT cells to
obtain 1U106 independent Bla-S-resistant transfectant colonies. After
three cycles of adhesion selection [7] and repeated single-colony iso-
lation, 13 stable revertants were obtained. The plasmid portions of the
transfected DNA in these revertant clones were recovered and ampli-
¢ed in bacteria as described previously [10]. Out of 22 plasmids thus
recovered, three clones with insert sizes of about 1.2 kb (20d-3), 1.0 kb
(8c-3) and 1.4 kb (6a-3), respectively, were found to give rise to £at
revertants when transfected into DT cells.
2.3. RNA blot hybridization
For tissue distribution analysis, the 32P-labeled 20d-3 (TFPI-2)
cDNA was hybridized to pre-blotted human tissue poly(A) mRNA
(Multiple Tissue Northern Blot, Clontech). The quality and quantity
of RNA samples were assessed by hybridization with 32P-labeled
L-actin cDNA. For other RNA blot hybridization experiments, 2 Wg
of poly(A) mRNA puri¢ed from cultured cells using the Quick Prep
Micro mRNA Puri¢cation kit (Promega) was analyzed according to
the standard protocol [22]. The same blot was analyzed successively
with the TFPI-2 probe, human H-ras probe in some cases, and L-actin
probe.
2.4. Immunoblot assay
To prepare conditioned medium (CM), cells (1.2U106 per 100 mm
dish) were plated, incubated overnight, rinsed with phosphate-bu¡-
ered saline (PBS; 4 mlU3) and further incubated in 11 ml serum-
free DME for 24 h. The culture supernatant was harvested, cleared
by low speed centrifugation and concentrated to 50 Wl with Centricon
10 (Amicon). To prepare cell lysates, the cells on the dish were rinsed
with PBS (4 mlU3) and detached by incubating for 20 min in 1.5 ml
of 1 mM EDTA in PBS. After suspension by pipetting, the cells were
harvested and lysed with 1 ml of 1% sodium dodecyl sulfate (SDS) in
Tris-bu¡ered saline (TBS). To prepare the extracellular matrix (ECM)
fraction, 1.5 ml of 1% SDS in TBS was added to the dish from which
the cells had been removed as described above. After swirling at room
temperature for 2 h, the solution was collected. Each of these samples
was diluted with one volume of 2USDS sample bu¡er and boiled for
5 min. The proteins were separated by SDS^polyacrylamide gel elec-
trophoresis (15%) and transferred onto PVDF membrane (Micron
Separations). After blocking with 4% non-fat dry milk in TBS con-
taining 0.01% Tween 20, the membrane was incubated with rabbit
polyclonal anti-TFPI-2 antibodies (provided by Drs. K. Udagawa
and Y. Miyagi, Yokohama City University) for 2 h. After TBS-wash-
ing, the membrane was incubated with alkaline phosphatase-conju-
gated monoclonal mouse anti-rabbit IgG (Promega) using nitro blue
tetrazolium and 5-bromo-3-indolyl phosphate as substrates.
2.5. Invasion and motility assays
For invasion assay, cells (7U105) suspended in DME containing
0.1% bovine serum albumin (BSA) were placed in the upper compart-
ment of BioCoat Matrigel Invasion Chamber (Collaborative). The
lower compartment was ¢lled with DME containing 10% FCS. After
incubation at 37‡C in a CO2 incubator for 24 h, the cells that had
penetrated the Matrigel-coated membrane were counted [23]. For mo-
tility assay, uncoated Transwell Chambers (Coster), instead of Matri-
gel chambers, were used and the cells that had migrated across the
membrane were counted after 6 h incubation.
2.6. Gelatin-zymography
Culture supernatants were prepared by incubating cells in DME
containing 0.1% BSA (volume: 300 Wl per 5U105 cells) at 37‡C for
6 h. Proteins in the conditioned media were separated, without prior
boiling, by electrophoresis through SDS^polyacrylamide (10%) gel
containing 1 mg/ml gelatin (Difco) under non-reducing conditions.
The proteins in the gel were renatured and stained as described pre-
viously [24].
2.7. Cell adhesion and reversion assays using CM and ECM
The protocol described previously [25] was adapted with some mod-
i¢cations. In brief, cells (5U105) were seeded onto a 60 mm dish and
incubated at 37‡C for 2 days. The culture supernatant (CM) was then
recovered and ¢ltered through 0.45 Wm membrane ¢lter (Millipore).
The cells were removed from the dish by treatment with 1 mM EDTA
in PBS for 20 min. After pipetting, the suspended cells were removed,
and each dish was checked for the complete detachment of the cells
under a phase-contrast microscope. To ¢x the remaining ECM, dishes
were dried for 30 min under a laminar £ow hood. For cell adhesion
assay, DT cells (2U105) suspended in the ¢ltered CM were seeded
onto the ECM-coated dish and incubated at 37‡C. After 90 min in-
cubation, £oating cells were thoroughly removed, and the dish was
Fig. 1. Reversion-inducing activity of 20d-3 (TFPI-2) cDNA. A:
Morphology of the parental DT cells (a), the primary revertant 20d-
3 (b), and the colonies obtained after transfection of control vector
(c, e) or one of the cDNA clones recovered from the 20d-3 cells (d,
f) into DT cells followed by selection with Bla-S for 7 days. Bars
represent 100 Wm. B: Frequency of £at colonies among total colo-
nies observed after transfection of control plasmid (vector) or 20d-
3-containing plasmid into DT cells. The data represent the summary
of three separate experiments.
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washed with PBS. The remaining cells were then detached using tryp-
sin/EDTA and counted. For reversion assay, DT cells (1U103) sus-
pended in the ¢ltered CM supplemented with 10% FCS were seeded
onto the ECM-coated dish and incubated at 37‡C in a CO2 incubator.
After 7 days incubation, the numbers of all colonies and £at colonies
were counted.
3. Results
3.1. Isolation of reversion-inducing cDNAs
A human placental cDNA expression library was screened
for clones inducing £at reversion when overexpressed in the
v-K-ras-transformed NIH3T3 cell line, DT, as described pre-
viously [10]. Three biologically active cDNA clones were ob-
tained. One of these, named 20d-3, was found to show the
highest reversion-inducing activity and therefore subjected to
further characterization.
A dose-dependent increase in the number of £at colonies
was observed when the 20d-3 plasmid DNA was transfected
into DT cells (Fig. 1). The £at transfectants, when isolated,
were found to show reduced proliferative potential both in
soft agar and in liquid medium as compared to the parental
DT cells, and their growth properties were closer to those of
untransformed NIH3T3 cells (data not shown). The nucleo-
tide sequence analysis revealed that the 20d-3 cDNA contains
the full coding sequence of TFPI-2 [12,14].
3.2. TFPI-2 gene expression is in£uenced by oncogenic ras
genes
Next we examined the expression of TFPI-2 mRNA in cell
lines and normal human tissues by RNA blot hybridization.
Endogenous TFPI-2 mRNA was undetectable in DT cells,
while two species of mRNA could be detected in DT cells
transfected with 20d-3 plasmid (Fig. 2A). Strong expression
of the transcripts of about 1.2 and 1.4 kb was detected in
human placenta, as expected from its alternative name, PP5
[14]. In addition, low level expression could be detected in a
wide variety of organs (Fig. 2B), which is consistent with the
earlier observation by Miyagi et al. using a limited number of
organs [26].
TFPI-2 transcript could also be detected in cultured normal
human ¢broblasts (MRC-5), whereas it was undetectable in a
human ¢brosarcoma cell line HT1080 [27] which is known to
harbor a mutationally activated N-ras gene [28] (Fig. 2C).
Interestingly, when we overexpressed an activated form of
human H-ras gene (H-ras12V) in MRC-5 cells, TFPI-2
mRNA was down-regulated (Fig. 2C). Thus, the low expres-
sion of TFPI-2 gene in HT1080 cells may be attributed, at
least in part, to the mutated N-ras oncogene.
TFPI-2 expression was also undetectable in the colon car-
cinoma-derived cell line SW480 [29] (Fig. 2C) which contained
mutationally activated K-ras oncogene [30]. It is, however,
hard to judge whether TFPI-2 gene was down-regulated in
these cells, since its expression in their normal counterpart,
colon mucosa, was originally low and barely detectable under
these conditions (Fig. 2B).
3.3. E¡ects of TFPI-2 expression on the growth properties of
HT1080 cells
To examine the role of TFPI-2 gene in the regulation of cell
growth and malignant behavior of the cells, we established
HT1080 cells transfected with an expression vector containing
the TFPI-2 cDNA. TFPI-2 mRNA could be detected in these
transfectants but not in the vector-transfected control cells
(Fig. 3A). Considerable fractions of TFPI-2 protein were
found to be secreted into the ECM and CM of the cDNA-
transfected cells (Fig. 3B). Cellular morphology, however, was
Fig. 2. Detection of TFPI-2 mRNA in cell lines and normal human tissues by RNA blot hybridization. A: Mouse cell lines. Poly(A) RNA
from parental DT cells (left lane) or the 20d-3-transfected DT cells (right lane) was probed with 20d-3 cDNA (top panel) and then re-probed
with L-actin cDNA (bottom panel). B: Normal human tissues. Human multiple tissue blots were probed with TFPI-2 cDNA (top panel) and
then with L-actin cDNA (bottom panel). C: Cultured human cells. Poly(A) RNA form MRC-5 (normal ¢broblast), MRC-5 infected with a
retroviral vector carrying the H-ras12V oncogene, HT1080 (¢brosarcoma) or SW480 (colon adenocarcinoma) were probed successively with H-
ras, TFPI-2 and L-actin cDNAs.
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not appreciably a¡ected in these transfectants (not shown);
the parental line itself was heterogeneous in morphology to
some extent.
Next we compared the growth properties of the vector-
transfected cells and 20d-3-transfected cells. First, we could
not detect any signi¢cant e¡ects on the ability of these pooled
transfectants to form colonies in soft agar (Fig. 3C). Second,
we could detect no signi¢cant di¡erence in their cell motility
(Fig. 3D). Interestingly, however, a signi¢cant suppression of
matrix invasion was observed in TFPI-2-expressing cells (Fig.
3E). To explore the reason for this e¡ect, we examined the
levels of gelatinase activities in the CM by gelatin-zymography
(Fig. 3F). Interestingly, the relative intensity of the 56 kDa
band corresponding to the mature, active form of matrix met-
alloproteinase-2 (MMP-2) was signi¢cantly reduced in TFPI-
2-expressing cells, irrespective of the substrate used for culti-
vation (i.e. collagen-coated or uncoated) (Fig. 3F).
3.4. TFPI-2 protein and £at reversion
To con¢rm the role of TFPI-2 protein in the £at reversion
Fig. 3. E¡ects of TFPI-2 expression in HT1080 cells. A: Detection of TFPI-2 mRNA in HT1080 cells stably transfected with control vector
(left lane) or the vector expressing TFPI-2 (right lane). The experimental conditions were similar to those in Fig. 2. B: TFPI-2 proteins in the
CM, cell lysate (CL) or ECM prepared from these transfectants were analyzed by immunoblot assay using anti-TFPI-2 polyclonal antibody.
C: E¡ects on anchorage-independent growth. The transfected cells plated in soft agar medium were incubated for 3 weeks, and the colonies
larger than 0.1 mm in diameter were scored (two independent experiments). D: E¡ects on cell motility (n = 6). E: E¡ects on invasive activity
(n = 12). Error bars in C, D and E represent S.E.M., and P values from Student’s t-test are also presented. F: E¡ects on secreted gelatinase
activities. The transfected cells were plated on a regular tissue culture dish (non-coated) or the dish coated with collagen type I (collagen), and
the culture supernatants were analyzed by gelatin-zymography. Positions of respective gelatinase species are indicated.
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initially observed in DT cells, we prepared both CM and
ECM either from control HT1080 cells, vector-transfected
cells or TFPI-2-transfected cells and observed the morphology
of DT cells incubated in the presence of these materials (Fig.
4). First, the CM and ECM prepared from TFPI-2-expressing
cells support the attachment of DT cells more e⁄ciently than
the CM and ECM from vector-transfected cells (Fig. 4A).
Second, after incubation for several days, DT cells form £at
colonies (Fig. 4B) at higher frequencies in the presence of CM
and ECM prepared from TFPI-2-expressing cells than in the
presence of CM and ECM from control cells (Fig. 4C). Ex-
periments with CM alone or ECM alone gave less clear results
(data not shown), suggesting cooperative e¡ects between these
components.
4. Discussion
In this study, we isolated the TFPI-2 cDNA as a transfor-
mation suppressor gene against a v-K-ras-transformed
NIH3T3 cell line. We also found that TFPI-2 gene is low in
the cells harboring activated ras oncogenes and the restored
expression of TFPI-2 gene in such tumor cells resulted in
suppression of their invasive behavior. These ¢ndings are con-
sistent with the model that TFPI-2 may represent the proteins
whose expression in normal cells is important for suppression
of malignant behavior and whose down-regulation due to on-
cogenic mutations would contribute to the expression of ma-
lignant phenotypes. Another example of such protein is the
large membrane glycoprotein RECK which we recently iden-
ti¢ed through similar expression cloning [10,11].
TFPI-2 contains serine protease inhibitor domains and se-
creted into CM and ECM. TFPI-2 protein may therefore play
a role in maintenance of ECM through direct inhibition of
ECM-degrading serine proteinases such as plasmin. Recently,
Rao et al. reported that ECM degradation could be inhibited
by recombinant TFPI-2 protein [31]. Iino et al. also reported
that anti-TFPI-2 antibody caused detachment of TFPI-2-ex-
pressing endothelial cells from culture £ask [32]. These results
are consistent with our ¢nding that TFPI-2 expression en-
hanced cell adhesion. We also found that the CM and ECM
derived from the cells expressing TFPI-2 protein enhanced cell
adhesion and induced morphological reversion of DT cells.
Likewise, Higgins et al. reported that another serine protein-
ase inhibitor, plasminogen activator inhibitor-1, induced £at
reversion of v-ras-transformed rat kidney cells [33]. All these
¢ndings point to the roles of TFPI-2 in cell adhesion and
morphological changes associated with cell transformation.
It is unclear at the moment how we could reconcile our
¢ndings and the ¢nding by Shinoda et al. that TFPI-2 stim-
ulates the proliferation of bovine aortic smooth muscle cells in
culture [18]. The question of whether these apparently oppo-
site results re£ect cell type-speci¢c action of TFPI-2 or the
manifestations of a common molecular mechanism should
be explored in future studies.
Several proteinase inhibitors have been implicated as meta-
stasis suppressors [34]. Our data suggest that TFPI-2 sup-
presses Matrigel invasion by down-regulating the levels of
secreted, active MMP-2. Baramova et al. reported that, be-
sides MT1-MMP, plasmin can be involved in the activation of
pro-MMP-2 [35]. Therefore, TFPI-2 may inhibit tumor inva-
sion by interfering this process. During the course of this
study, Rao et al. reported that the exogenous addition of
recombinant TFPI-2 protein inhibited cell invasion in vitro
[31], further supporting our interpretation that the secreted
product of the transfected 20d-3 cDNA itself was responsible
for the observed inhibition of invasion.
TFPI-2 gene has been mapped on human chromosome
7q22 [36]. Loss of this region is observed in many types of
Fig. 4. E¡ects of TFPI-2 expression on cell adhesion. A: E¡ects of
CM and ECM from transfected HT1080 cells on substrate attach-
ment of DT cells. DT cells were plated in the presence of CM and
ECM prepared from the HT1080 cells transfected with control vec-
tor or the vector expressing TFPI-2 gene, and after 1.5 h, cells at-
tached to the dish were counted (n = 4). B: Morphology of the DT
cells incubated for 7 days in the presence of CM and ECM pre-
pared from the vector-transfected HT1080 cells (a) or the TFPI-2-
expressing cells (b). C: DT cells were plated onto regular tissue cul-
ture dishes with fresh medium (Control) or in the presence of CM
and ECM from the vector-transfected HT1080 cells (Vector) or the
TFPI-2-expressing cells (TFPI-2). After incubation for 7 days, the
ratio of £at colonies and total colonies was determined. The data
represent the summary of two independent experiments.
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human tumors [36]. Miyagi et al. reported that the TFPI-2
gene expression was detectable in di¡erentiated ovarian carci-
noma cell lines, but undetectable in undi¡erentiated lines [26].
Also, Udagawa et al. reported that the TFPI-2 gene expres-
sion was undetectable in several choriocarcinoma cell lines
[37]. These ¢ndings suggest possible involvement of TFPI-2
gene mutations and/or down-regulation in human carcinogen-
esis. Thus, it would be of interest to study possible correlation
between the levels of TFPI-2 gene expression and the prog-
nosis of the patients in various types of tumors.
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